Results 11 to 20 of about 1,927 (190)

Photopharmacology of Antimitotic Agents [PDF]

open access: yesInternational Journal of Molecular Sciences, 2022
Antimitotic agents such as the clinically approved vinca alkaloids, taxanes and epothilone can arrest cell growth during interphase and are therefore among the most important drugs available for treating cancer. These agents suppress microtubule dynamics and thus interfere with intracellular transport, inhibit cell proliferation and promote cell death.
Susanne Kirchner, Zbigniew Pianowski
openaire   +6 more sources

Remote control of glucose homeostasis in vivo using photopharmacology [PDF]

open access: yesScientific Reports, 2017
Photopharmacology describes the use of light to precisely deliver drug activity in space and time. Such approaches promise to improve drug specificity by reducing off-target effects.
Zenobia B. Mehta   +9 more
doaj   +3 more sources

Rational Design in Photopharmacology with Molecular Photoswitches [PDF]

open access: yesAngewandte Chemie, 2023
AbstractPhotopharmacology is an attractive approach for achieving targeted drug action with the use of light. In photopharmacology, molecular photoswitches are introduced into the structure of biologically active small molecules to allow for the optical control of their potency.
Piermichele Kobauri   +3 more
openaire   +4 more sources

Biaryl sulfonamides as cisoid azosteres for photopharmacology [PDF]

open access: yesChemical Communications, 2021
Biaryl sulfonamides are excellent candidates for the azologization approach that yields photoswitchable drugs more active in their metastable cis state, compared to the stable trans state.
Piermichele Kobauri   +7 more
openaire   +5 more sources

Photopharmacology [PDF]

open access: yes, 2014
Veel problemen die gerelateerd zijn aan geneesmiddelen, zoals bijwerkingen en resistentie, worden veroorzaakt doordat medicijnen altijd actief zijn: geneesmiddelen zijn actief in het hele lichaam waardoor bijwerkingen optreden en ze zijn zelfs nog actief in het milieu waardoor bacteriële resistentie kan ontstaan.
Velema, Wim
core   +7 more sources

Rational drug design in photopharmacology [PDF]

open access: yes, 2022
Photopharmacology uses light to regulate the biological activity of drugs. This precise control is obtained through the incorporation of molecular photoswitches into bioactive molecules. A major challenge for photopharmacology is the rational design of photoswitchable drugs that show light-induced activation. Computer-aided drug design is an attractive
Kobauri, Piermichele
openaire   +5 more sources

Photochemical Restoration of Light Sensitivity in the Degenerated Canine Retina

open access: yesPharmaceutics, 2022
Photopharmacological compounds such as azobenzene-based photoswitches have been shown to control the conductivity of ionic channels in a light-dependent manner and are considered a potential strategy to restore vision in patients with end-stage ...
Sergei Nikonov   +9 more
doaj   +1 more source

Photopharmacology for vision restoration

open access: yesCurrent Opinion in Pharmacology, 2022
Blinding diseases that are caused by degeneration of rod and cone photoreceptor cells often spare the rest of the retinal circuit, from bipolar cells, which are directly innervated by photoreceptor cells, to the output ganglion cells that project axons to the brain.
Michael H, Berry   +5 more
openaire   +2 more sources

Photopharmacology: Beyond Proof of Principle [PDF]

open access: yesJournal of the American Chemical Society, 2014
Pharmacotherapy is often severely hindered by issues related to poor drug selectivity, including side effects, environmental toxicity, and the emergence of resistance. Lack of selectivity is caused by the inability to control drug activity in time and space.
Willem A. Velema   +2 more
openaire   +2 more sources

Investigation on Novel E/Z 2-Benzylideneindan-1-One-Based Photoswitches with AChE and MAO-B Dual Inhibitory Activity

open access: yesMolecules, 2023
The multitarget therapeutic strategy, as opposed to the more traditional ‘one disease-one target-one drug’, may hold promise in treating multifactorial neurodegenerative syndromes, such as Alzheimer’s disease (AD) and related dementias.
Marco Paolino   +11 more
doaj   +1 more source

Home - About - Disclaimer - Privacy